Trial reportLeukemia2007
Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features.
Trial report in Leukemia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02991066 (Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia), which is not on this map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review.Thrombosis research · 2018Pooled it
- Leukemia and Risk of Venous Thromboembolism: A Meta-analysis and Systematic Review of 144 Studies Comprising 162,126 Patients.Scientific reports · 2017Pooled it
- A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study.Haematologica · 2026Article
- Thromboembolism in adult patients with acute promyelocytic leukemia: clinical characteristics, risk factors, and a predictive nomogram.Annals of hematology · 2025Article
- Article
- Biochemical risk factors and outcomes of acute promyelocytic leukemia patients with thrombotic events: a matched pair analysis.Journal of thrombosis and thrombolysis · 2024Article
- Cancer-associated thrombosis in hematologic malignancies.International journal of hematology · 2024Review
- Cellular hierarchy insights reveal leukemic stem-like cells and early death risk in acute promyelocytic leukemia.Nature communications · 2024Article
- Arteriovenous thrombosis, a complication of induction therapy with all-trans retinoic acid for acute promyelocytic leukemia: A case report.Clinical case reports · 2023Article
- Review
- Simplified predictive scores for thrombosis and bleeding complications in newly diagnosed acute leukemia patients.Thrombosis journal · 2023Article
- Multi-omics and machine learning reveal context-specific gene regulatory activities of PML::RARA in acute promyelocytic leukemia.Nature communications · 2023Article
- Realgar (AsAging · 2022Article
- A risk score based on real-world data to predict early death in acute promyelocytic leukemia.Haematologica · 2022Article
- Budd-Chiari Syndrome as an Initial Presentation of Non-Promyelocytic Acute Myelogenous Leukemia.Gastroenterology research · 2022Article
- Risk factors of thrombosis in Chinese subjects with acute promyelocytic leukemia.Thrombosis journal · 2021Article
- Analysing "tear-drop" prints of acute promyelocytic leukemia (APML): immunophenotypic prognostication of APML by FCM.American journal of blood research · 2021Article
- Acute promyelocytic leukemia presenting as recurrent venous and arterial thrombotic events: a case report and review of the literature.Journal of community hospital internal medicine perspectives · 2021Article
- Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?Frontiers in medicine · 2021Review
- Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.International journal of hematology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the occurrence of thrombosis in acute promyelocytic leukemia (APL) has been reported during retinoic acid treatment, no studies carried out in large clinical cohorts have specifically addressed this issue. We analyzed 124 APL patients treated with the all-trans retinoic acid and idarubicin protocol and compared clinico-biologic characteristics of 11 patients who developed thrombosis with those of 113 patients who had no thrombosis. In seven patients, the events were recorded during induction, whereas in four patients deep vein thrombosis occurred in the post-induction phase. Comparison of clinico-biological characteristics of patients with and without thrombosis revealed in the former group higher median white blood cell (WBC) count (17 x 10(9)/l, range 1.2-56, P=0.002), prevalence of the bcr3 transcript type (72 vs 48%, P=0.01), of FLT3-ITD (64 vs 28%, P=0.02), CD2 (P=0.0001) and CD15 (P=0.01) expression. No correlation was found with sex, age, French-American-British subtype, all-trans-retinoic acid syndrome or with thrombophilic state that was investigated in 5/11 patients. Our findings suggest that, in APL patients consistent biologic features of leukemia cells may predict increased risk of developing thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.